Article Text

Download PDFPDF
An immunohistochemical study of the incidence and significance of C-erbB-2 oncoprotein overexpression in ovarian neoplasia
  2. N. TODD*,
  3. C. H. BUCKLEY*,
  4. B. A. GUSTERSON and
  5. H. FOX*
  1. *Departments of Pathology, University of Manchester and St Mary's Hospital, Manchester
  2. Institute of Cancer Research, Royal Cancer Hospital, Sutton, UK
  1. Address for correspondence: Professor H. Fox, Department of Pathological Sciences, University of Manchester, Stopford Building, Oxford Road, Manchester M13 9PT, UK.


An immunohistochemical study was made of overexpression of the c-erbB-2 oncogene product in benign, borderline and malignant epithelial neoplasms of the ovary. Positive staining was found only in 2 of 15 mucinous tumors of borderline malignancy and in 11 of 16 mucinous adenocarcinomas. Positive staining was not detected in serous or endometrioid tumors. Amongst the group of mucinous adenocarcinomas, no correlation could be found between overexpression of c-erbB-2 oncoprotein and tumor stage, tumor differentiation or patient survival. It is concluded that overexpression of c-erbB-2 oncoprotein is not an adverse prognostic factor in ovarian adenocarcinoma.

  • C-erbB-2 oncoprotein
  • ovarian neoplasia

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.